238 related articles for article (PubMed ID: 28938164)
1. Multifunctional superparamagnetic nanoparticles conjugated with fluorescein-labeled designed ankyrin repeat protein as an efficient HER2-targeted probe in breast cancer.
Li DL; Tan JE; Tian Y; Huang S; Sun PH; Wang M; Han YJ; Li HS; Wu HB; Zhang XM; Xu YK; Wang QS
Biomaterials; 2017 Dec; 147():86-98. PubMed ID: 28938164
[TBL] [Abstract][Full Text] [Related]
2. Comparison of tumor‑targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2.
Vorobyeva A; Sсhulga A; Konovalova E; Güler R; Mitran B; Garousi J; Rinne S; Löfblom J; Orlova A; Deyev S; Tolmachev V
Int J Oncol; 2019 Apr; 54(4):1209-1220. PubMed ID: 30968147
[TBL] [Abstract][Full Text] [Related]
3. Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging.
Goldstein R; Sosabowski J; Livanos M; Leyton J; Vigor K; Bhavsar G; Nagy-Davidescu G; Rashid M; Miranda E; Yeung J; Tolner B; Plückthun A; Mather S; Meyer T; Chester K
Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):288-301. PubMed ID: 25391547
[TBL] [Abstract][Full Text] [Related]
4. Indirect Radioiodination of DARPin G3 Using N-succinimidyl-
Vorobyeva A; Schulga A; Rinne SS; Günther T; Orlova A; Deyev S; Tolmachev V
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234471
[TBL] [Abstract][Full Text] [Related]
5. Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors.
Vorobyeva A; Bragina O; Altai M; Mitran B; Orlova A; Shulga A; Proshkina G; Chernov V; Tolmachev V; Deyev S
Contrast Media Mol Imaging; 2018; 2018():6930425. PubMed ID: 29977173
[TBL] [Abstract][Full Text] [Related]
6. A Comparative Study of Receptor-Targeted Magnetosome and HSA-Coated Iron Oxide Nanoparticles as MRI Contrast-Enhancing Agent in Animal Cancer Model.
Erdal E; Demirbilek M; Yeh Y; Akbal Ö; Ruff L; Bozkurt D; Cabuk A; Senel Y; Gumuskaya B; Algın O; Colak S; Esener S; Denkbas EB
Appl Biochem Biotechnol; 2018 May; 185(1):91-113. PubMed ID: 29082480
[TBL] [Abstract][Full Text] [Related]
7. Comparative Preclinical Evaluation of HYNIC-Modified Designed Ankyrin Repeat Proteins
Larkina M; Varvashenya R; Yuldasheva F; Plotnikov E; Bezverkhniaia E; Tretyakova M; Zelchan R; Schulga A; Konovalova E; Vorobyeva A; Belousov M; Orlova A; Tolmachev V; Deyev S
Mol Pharm; 2024 Apr; 21(4):1919-1932. PubMed ID: 38557163
[TBL] [Abstract][Full Text] [Related]
8. Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties.
Deyev S; Vorobyeva A; Schulga A; Proshkina G; Güler R; Löfblom J; Mitran B; Garousi J; Altai M; Buijs J; Chernov V; Orlova A; Tolmachev V
Mol Pharm; 2019 Mar; 16(3):995-1008. PubMed ID: 30608701
[TBL] [Abstract][Full Text] [Related]
9. In Vivo HER2-Targeted Magnetic Resonance Tumor Imaging Using Iron Oxide Nanoparticles Conjugated with Anti-HER2 Fragment Antibody.
Ding N; Sano K; Kanazaki K; Ohashi M; Deguchi J; Kanada Y; Ono M; Saji H
Mol Imaging Biol; 2016 Dec; 18(6):870-876. PubMed ID: 27351762
[TBL] [Abstract][Full Text] [Related]
10. Development of the Tumor-Specific Antigen-Derived Synthetic Peptides as Potential Candidates for Targeting Breast and Other Possible Human Carcinomas.
Okarvi SM; AlJammaz I
Molecules; 2019 Aug; 24(17):. PubMed ID: 31470531
[TBL] [Abstract][Full Text] [Related]
11. Sortase-Mediated Site-Specific Conjugation and
Fay R; Törő I; Schinke AL; Simic B; Schaefer JV; Dreier B; Plückthun A; Holland JP
Mol Pharm; 2022 Oct; 19(10):3576-3585. PubMed ID: 35434995
[TBL] [Abstract][Full Text] [Related]
12. Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with
Cai Z; Yook S; Lu Y; Bergstrom D; Winnik MA; Pignol JP; Reilly RM
Pharm Res; 2017 Mar; 34(3):579-590. PubMed ID: 27987070
[TBL] [Abstract][Full Text] [Related]
13. Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 with
Larkina M; Plotnikov E; Bezverkhniaia E; Shabanova Y; Tretyakova M; Yuldasheva F; Zelchan R; Schulga A; Konovalova E; Vorobyeva A; Garousi J; Gräslund T; Belousov M; Tolmachev V; Deyev S
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362226
[TBL] [Abstract][Full Text] [Related]
14. Phase I Trial of
Bragina O; Chernov V; Schulga A; Konovalova E; Garbukov E; Vorobyeva A; Orlova A; Tashireva L; Sörensen J; Zelchan R; Medvedeva A; Deyev S; Tolmachev V
J Nucl Med; 2022 Apr; 63(4):528-535. PubMed ID: 34385343
[TBL] [Abstract][Full Text] [Related]
15. Detection of breast cancer cells using targeted magnetic nanoparticles and ultra-sensitive magnetic field sensors.
Hathaway HJ; Butler KS; Adolphi NL; Lovato DM; Belfon R; Fegan D; Monson TC; Trujillo JE; Tessier TE; Bryant HC; Huber DL; Larson RS; Flynn ER
Breast Cancer Res; 2011 Nov; 13(5):R108. PubMed ID: 22035507
[TBL] [Abstract][Full Text] [Related]
16. Fe
Yin Q; Gao X; Zhang H; Zhang Z; Yu X; He J; Shi G; Hao L
Biomed Mater; 2024 Apr; 19(3):. PubMed ID: 38626777
[TBL] [Abstract][Full Text] [Related]
17. Multivalent exposure of trastuzumab on iron oxide nanoparticles improves antitumor potential and reduces resistance in HER2-positive breast cancer cells.
Truffi M; Colombo M; Sorrentino L; Pandolfi L; Mazzucchelli S; Pappalardo F; Pacini C; Allevi R; Bonizzi A; Corsi F; Prosperi D
Sci Rep; 2018 Apr; 8(1):6563. PubMed ID: 29700387
[TBL] [Abstract][Full Text] [Related]
18. Triple Therapy of HER2
Zolata H; Afarideh H; Davani FA
Cancer Biother Radiopharm; 2016 Nov; 31(9):324-329. PubMed ID: 27831759
[TBL] [Abstract][Full Text] [Related]
19. Anti-HER2 antibody and ScFvEGFR-conjugated antifouling magnetic iron oxide nanoparticles for targeting and magnetic resonance imaging of breast cancer.
Chen H; Wang L; Yu Q; Qian W; Tiwari D; Yi H; Wang AY; Huang J; Yang L; Mao H
Int J Nanomedicine; 2013; 8():3781-94. PubMed ID: 24124366
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
